An observational study in Obesity & Overweight and Diabetes (DM), sponsored by Ohio State University. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-24.
Sponsored by Ohio State University · Observational
Among 23 studies in Obesity by Ohio State University — 1 open to participants now, 3 under way, none of them phase 3. Obesity · Ohio State University.
Among the 23 studies in Obesity by Ohio State University, this one is the only one that started in 2026, is one of 4 observational ones, and was the 23rd registered.
11,522 studies on the registry are indexed under Obesity; 2,033 are open to participants now.
This study's planned enrollment of 300 is above the median of 114 across 2,154 observational studies indexed under Obesity.
Browse Obesity studies →1 of the 23 studies in Obesity by Ohio State University is open now, in 1 country. Each count lists the studies.
Of the 1,336 Obesity studies recruiting now, 377 (28%) set no upper age limit and 856 (64%) stop at 75 or younger; 168 take children under 18; 491 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →23 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 1 started in 2026.
Median enrollment 78 across the 19 interventional studies, 250 across the 4 observational. Of the 20 that completed or were terminated, 13 (65%) have results posted.
Ohio State University is the lead sponsor of 663 studies on the registry; 148 are open to participants now.
Of its 67 completed or terminated interventional studies of FDA-regulated products, 49 (73%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 23 studies in Obesity by Ohio State University, from their registry updates:
This study examines how adults who take a GLP-1 receptor agonist medication (such as semaglutide [Ozempic, Wegovy, Rybelsus], liraglutide [Saxenda, Victoza], or tirzepatide [Mounjaro, Zepbound]) perform resistance (strength) training before and after starting their medication.
GLP-1 medications are being prescribed more and more often to help people manage type 2 diabetes and lose weight. These medications work well, but a known side effect is that people can lose lean (muscle) tissue along with fat. Losing muscle can make it harder to move, do everyday tasks, and stay strong as we age. Resistance training, things like lifting weights, using resistance bands, or doing push-ups and squats, is the most effective way to keep and build muscle. Yet most adults in the United States do not meet the recommended amount of resistance training, and very little is known about the resistance training habits of people who take GLP-1 medications.
The purpose of this research is to systematically collect information from adults using GLP-1 medications so we can better understand: how often they do resistance training before and after starting the medication; what their sessions look like (frequency, duration, intensity, muscle groups); whether their resistance training is linked to how strong they feel and how well they can carry out daily activities; and what makes resistance training easier or harder while on a GLP-1 medication.
Findings will help doctors, dietitians, exercise professionals, and researchers design better guidance and interventions to protect muscle mass, physical function, and quality of life in people using GLP-1 medications.
Who can join: Adults 18 years or older who are currently taking a GLP-1 receptor agonist medication for type 2 diabetes, overweight or obesity, or weight management, and who have been on the medication for at least three months at a stable dose. Participants must be able to read and respond to the survey in English. People who are pregnant or planning bariatric surgery within the next three months are not eligible.
What participants will do: The study is a single, anonymous, online survey. Interested individuals click the survey link, review a short consent page, and indicate their willingness to participate. Eligible participants then answer questions about their background, current health, GLP-1 medication and dose, resistance training habits before and after starting the medication, self-reported strength and function, and things that make resistance training easier or harder. There are no in-person visits, no exercise tests, and no blood draws.
How long it takes: About 10 minutes total, in one online session. There is no follow-up after the survey and no compensation is offered.
Data privacy: The survey is anonymous. No names, email addresses, or IP addresses are collected or linked to responses. The survey runs on Qualtrics, a secure, institution-approved platform hosted on Ohio State University servers.
The research team hopes to enroll up to 200-300 adults across the United States.
Background and Rationale Glucagon-like peptide-1 (GLP-1) is a naturally occurring hormone released from enteroendocrine cells after a meal. It slows gastric emptying, limits maximum nutrient absorption, and helps prevent weight gain. GLP-1's actions also include preventing beta-cell death, promoting beta-cell proliferation, and regulating glucose metabolism. Originally used to improve outcomes in people with type 2 diabetes, GLP-1 receptor agonists (GLP-1RAs) have increasingly been prescribed for chronic weight management in individuals with overweight or obesity, with agents such as liraglutide 3 mg and semaglutide 2.4 mg approved for people with a body mass index of at least 30 kg/m2, or 27 kg/m2 with weight-related comorbidities. From 2019 to 2023, use of GLP-1RAs for weight loss in the United States rose from approximately 21,000 to 174,000 users, an increase of more than 700%.
A recognized side effect of GLP-1RA therapy is a reduction in lean tissue mass. Losses in lean mass can impair quality of life and physical function by decreasing strength, slowing gait speed, and increasing fatigue. Reductions in muscle mass may also heighten fall risk, worsen metabolic health, and limit patients' ability to perform activities of daily living independently.
Resistance training (RT) is the most effective strategy for preserving and building muscle mass and strength. The American College of Sports Medicine (ACSM) recommends that adults engage in RT at least 2-3 times per week at moderate to vigorous intensity, focusing on all major muscle groups. However, national surveillance data indicate that only about 30% of U.S. adults meet the muscle-strengthening guidelines. Despite emerging evidence that combining GLP-1RAs with structured exercise - particularly RT - can mitigate lean mass loss and optimize long-term metabolic and functional outcomes, little is known about patients' RT behavior before and after initiating GLP-1RA therapy.
This study aims to systematically collect self-reported data from adults using GLP-1RAs on their RT participation and adherence to ACSM-aligned guidelines before and after starting the medication, in order to identify gaps in RT engagement and generate practical recommendations for researchers and practitioners seeking to prevent lean mass loss, preserve physical function, and improve quality of life in this growing patient population.
Specific Aims and Hypotheses Aim 1: Quantify the prevalence of resistance training participation among adults using GLP-1RAs, both before and after initiating GLP-1RA therapy.
Aim 2: Characterize patterns of RT dosage (frequency, intensity, type, and volume) in GLP-1RA users and compare them to ACSM-aligned recommendations.
- Hypothesis 2: Most GLP-1RA users who report RT perform it at a frequency and intensity below ACSM guidelines for optimal lean mass preservation.
Aim 3: Explore associations between RT participation and self-reported outcomes related to lean mass preservation, physical function, and quality of life in GLP-1RA users.
- Hypothesis 3: GLP-1RA users who meet RT guidelines report better perceived strength, functional capacity (e.g., ability to perform daily tasks), and health-related quality of life than those who do not perform RT.
Aim 4: Identify patient-reported barriers and facilitators to engaging in RT while using GLP-1RAs, to inform future intervention development.
- Hypothesis 4: Common barriers will include lack of knowledge about RT benefits during GLP-1RA therapy, limited access to equipment or programs, and fear of injury.
Study Design This is a cross-sectional, anonymous, online survey study. Adults currently using GLP-1RAs will complete a single online questionnaire assessing RT participation before and after starting GLP-1RA therapy, RT dosage patterns, perceived functional and quality-of-life outcomes, and perceived barriers and facilitators to RT. There are no in-person visits, no interventions, and no biological specimen collection. All data are self-reported in one online session lasting approximately 10 minutes.
Recruitment Potential participants will be identified through multiple channels, including: flyers and posters placed in relevant clinical settings (e.g., endocrinology, primary care); social media outreach (e.g., posts or advertisements targeting adults using GLP-1RAs); and clinic-based outreach in which the study team provides IRB-approved recruitment flyers and study links to participating clinic staff (e.g., front desk staff, providers, care coordinators) for posting in clinic waiting areas or distribution to potentially interested patients during routine visits. The study team will not pre-screen or identify patients via medical records, and clinic staff will not share any patient identifiers with the study team. Interested patients will self-refer by accessing the survey link from the flyer or handout. The study team will not access, request, or use any medical records or protected health information (PHI) for recruitment, screening, enrollment, or analysis.
Procedures The full participant workflow is as follows: (1) potential participants encounter an IRB-approved recruitment flyer, poster, social media post/advertisement, or clinic-distributed handout describing the study and listing a secure survey URL and/or QR code; (2) interested individuals self-initiate contact by clicking the link or scanning the QR code on a device of their choice, at a time and place of their choosing; (3) the link directs them to the electronic informed consent page on the institution-approved survey platform (Qualtrics) hosted on Ohio State University secure servers; (4) individuals who indicate willingness to participate by selecting "I agree to participate" proceed to brief eligibility screening; (5) individuals who meet all inclusion and no exclusion criteria proceed automatically to the main questionnaire, while ineligible individuals are routed to a thank-you/exit message; (6) eligible participants complete the one-time questionnaire and exit the platform.
The main questionnaire assesses: demographic and general health information; current height and weight and weight at the time of GLP-1RA initiation; specific GLP-1RA medication, indication, start date, starting dose, and current dose; resistance training habits in a usual week before starting the GLP-1RA medication; resistance training habits in a usual week since starting the GLP-1RA medication; self-reported muscular strength, ability to perform activities of daily living, fatigue, overall health, and quality of life; and perceived barriers and facilitators to resistance training while using a GLP-1RA. Resistance training is assessed using the Muscle-Strengthening Exercise Questionnaire (MSEQ; Shakespear-Druery et al., 2022) Long Form, which captures frequency, session duration, intensity (0-10 OMNI-Resistance Exercise Scale), muscle groups targeted, and type of resistance exercise (weight machines, bodyweight exercises, resistance bands or free weights, and holistic exercises). Items are presented verbatim with the recall anchor adapted from "in a usual week" to "in a usual week BEFORE you started your GLP-1 medication" and "in a usual week SINCE you started your GLP-1 medication" to enable a within-person pre/post comparison.
Consent Electronic informed consent will be obtained at the beginning of the online survey using the IRB-approved online consent script (HRP-537 template). Because the click-to-agree mechanism does not capture a legally valid electronic signature, a Waiver of Documentation of Consent under 45 CFR 46.117(c) has been granted. The research presents no more than minimal risk and involves no procedures for which written consent is normally required outside of the research context.
Privacy and Confidentiality The survey is anonymous. No direct or indirect identifiers (name, email address, IP address) are collected or linked to survey responses. Qualtrics is configured to disable IP address collection and to use anonymous response settings. Data are stored on secure, password-protected Ohio State University servers, in project folders restricted to authorized study personnel listed on the approved IRB protocol. The analytic dataset is anonymous and contains no identifiable components. Consistent with university policy, research data are retained for at least five years after study closure.
Sample Size The target sample size is 200-300 consented participants. This number was selected based on feasibility and the need for sufficient precision to estimate the prevalence of resistance training participation among adults using GLP-1RAs, and to allow exploratory comparisons between participants who do and do not meet resistance training guidelines. Eligibility screening occurs after electronic consent; every consented individual that meets eligibility criteria counts toward the 300-participant enrollment ceiling.
Statistical Analysis Descriptive statistics will summarize participant demographics, GLP-1RA characteristics, and resistance training behaviors. Primary study questions will be addressed using paired analyses comparing resistance training status before and after GLP-1RA initiation. Categorical outcomes will be analyzed using McNemar's test, and continuous or ordinal outcomes using paired t-tests or Wilcoxon signed-rank tests based on data distribution. Associations between resistance training participation and self-reported outcomes (perceived strength, functional capacity, fatigue, quality of life) will be examined using bivariate comparisons and regression analyses. Open-ended responses, if collected, will be grouped using content analysis to identify common barriers and facilitators.
Risks, Benefits, and Compensation The study is minimal risk. The primary foreseeable risk is a potential breach of confidentiality, which is mitigated through anonymous data collection on a secure, institution-approved platform with encrypted transmission and disabled IP-address collection. Participants may experience minor psychological discomfort answering questions about weight, physical activity, or health, and may skip any question or exit the survey at any time. There are no direct medical or therapeutic benefits to individual participants. No compensation is offered.
Adults residing in the United States who are current users of GLP-1 receptor agonist medications for type 2 diabetes, overweight or obesity, and/or weight management. Participants are recruited from community and online settings rather than from a single physical site. Sources include: IRB-approved flyers and posters displayed in relevant clinical settings (e.g., endocrinology, primary care) and community locations; social media outreach (posts and advertisements) directed at adults using GLP-1 receptor agonist medications; and clinic-based outreach in which participating clinic staff post handouts in waiting areas or distribute them to potentially interested patients during routine visits. Interested individuals self-refer by accessing an anonymous online Qualtrics survey link. The study team does not pre-screen, identify, or contact patients directly, and does not access medical records or protected health information at any point.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adults currently taking a GLP-1 receptor agonist (GLP-1RA) medication for at least 3 months at a stable dose (e.g., semaglutide, liraglutide, tirzepatide, dulaglutide, or exenatide) complete a single, anonymous, online questionnaire administered via Qualtrics on Ohio State University secure servers. The survey (\~10 minutes) collects self-reported data on demographics, general health, current GLP-1RA medication with starting and current dose, height and weight, resistance training habits in a usual week before and since starting GLP-1RA therapy (assessed with the Muscle-Strengthening Exercise Questionnaire - Long Form; Shakespear-Druery et al., 2022), perceived muscular strength, activities of daily living, fatigue, quality of life, and barriers/facilitators to resistance training. No in-person visits, physical measurements, biospecimen collection, or follow-up contact are performed.
Also known as: GLP-1RA
This study also gives Semaglutide, Tirzepatide. No intervention listed here names it: that was found by reading the record.
Change in Resistance Training Status Before Versus Since GLP-1 Receptor Agonist Initiation
Resistance training (RT) status is assessed via the Muscle-Strengthening Exercise Questionnaire - Long Form (MSEQ-Long; Shakespear-Druery et al., 2022), which captures weekly frequency (days/week), session duration (minutes/session), intensity (OMNI-RES 0-10 scale), muscle groups targeted (7 major groups), and type of muscle-strengthening exercise across four modes (weight machines, bodyweight, resistance bands or free weights, holistic). Each participant reports RT during a usual week BEFORE starting their GLP-1 receptor agonist medication and during a usual week SINCE starting the medication. The primary outcome is the proportion of participants meeting ACSM muscle-strengthening guidelines (≥ 2 days per week engaging all major muscle groups) at each recall period, and the within-person change between the two recall periods.
Time frame: Day 1
Resistance Training Dosage Patterns Compared to ACSM Guidelines
Distributions of MSEQ-Long weekly frequency, session duration, intensity, muscle groups targeted, and exercise type, compared to ACSM adult muscle-strengthening recommendations, at each recall period.
Time frame: Day 1
Plan to share: Undecided — This study is a one-time anonymous online survey. No participant identifiers are collected or linked to responses at any point, so ICMJE IPD is not applicable. Aggregate and summary-level results will be shared through peer-reviewed publications and scientific presentations. The anonymous dataset is retained on secure OSU servers, accessible only to the study team listed on the approved IRB protocol (STUDY20260750).
Started Jun 2026 (actual). Primary completion is estimated for Oct 2026, 4 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.